Gene therapy for inborn errors of metabolism

Batten disease

Dolan Sondhi, Ronald Crystal, Stephen M. Kaminsky

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

The development of a gene therapy for inborn errors of metabolism is a multifaceted challenge that rides on organizational, fi nancial, and scientifi c issues.Using our experience with developing a gene therapy strategy for Batten disease [late infantile neuronal ceroid lipofuscinosis (LINCL), CLN2 disease], these factors are described in the context of the: (1) development of a therapeutic concept for a target disease; (2) pathway to proof of concept via preclinical studies; (3) translation to clinical development; (4) funding and the associated restrictions; (5) assembly of the clinical team; (6) regulatory and compliance requirements; and (7) the iterative process of using lessons learned to inform the next generation therapy. Our experience with each of these factors is demonstrated from our development and clinical translation for two generations of drug product applied to this fatal childhood disorder.Outlined are the descriptions of the hurdles encountered and our solutions, which should be informative for those who seek to develop a gene therapy for a rare disease.

Original languageEnglish
Title of host publicationTranslational Neuroscience
Subtitle of host publicationFundamental Approaches for Neurological Disorders
PublisherSpringer US
Pages111-129
Number of pages19
ISBN (Electronic)9781489976543
ISBN (Print)9781489976529
DOIs
Publication statusPublished - 1 Jan 2016
Externally publishedYes

Fingerprint

inherited metabolic diseases
Neuronal Ceroid-Lipofuscinoses
Inborn Errors Metabolism
gene therapy
Genetic Therapy
therapeutics
Rare Diseases
childhood
funding
compliance
Compliance
drugs
Therapeutics
Pharmaceutical Preparations

Keywords

  • AAV vectors
  • Batten disease
  • Central nervous system
  • Experimental therapies
  • Gene therapy
  • Lysosomal storage disorders
  • Phase I clinical trials in academic setting
  • Preclinical development
  • Translational medicine

ASJC Scopus subject areas

  • Medicine(all)
  • Neuroscience(all)
  • Agricultural and Biological Sciences(all)

Cite this

Sondhi, D., Crystal, R., & Kaminsky, S. M. (2016). Gene therapy for inborn errors of metabolism: Batten disease. In Translational Neuroscience: Fundamental Approaches for Neurological Disorders (pp. 111-129). Springer US. https://doi.org/10.1007/978-1-4899-7654-3_7

Gene therapy for inborn errors of metabolism : Batten disease. / Sondhi, Dolan; Crystal, Ronald; Kaminsky, Stephen M.

Translational Neuroscience: Fundamental Approaches for Neurological Disorders. Springer US, 2016. p. 111-129.

Research output: Chapter in Book/Report/Conference proceedingChapter

Sondhi, D, Crystal, R & Kaminsky, SM 2016, Gene therapy for inborn errors of metabolism: Batten disease. in Translational Neuroscience: Fundamental Approaches for Neurological Disorders. Springer US, pp. 111-129. https://doi.org/10.1007/978-1-4899-7654-3_7
Sondhi D, Crystal R, Kaminsky SM. Gene therapy for inborn errors of metabolism: Batten disease. In Translational Neuroscience: Fundamental Approaches for Neurological Disorders. Springer US. 2016. p. 111-129 https://doi.org/10.1007/978-1-4899-7654-3_7
Sondhi, Dolan ; Crystal, Ronald ; Kaminsky, Stephen M. / Gene therapy for inborn errors of metabolism : Batten disease. Translational Neuroscience: Fundamental Approaches for Neurological Disorders. Springer US, 2016. pp. 111-129
@inbook{791f83103f7b4eb0ab341df97140a152,
title = "Gene therapy for inborn errors of metabolism: Batten disease",
abstract = "The development of a gene therapy for inborn errors of metabolism is a multifaceted challenge that rides on organizational, fi nancial, and scientifi c issues.Using our experience with developing a gene therapy strategy for Batten disease [late infantile neuronal ceroid lipofuscinosis (LINCL), CLN2 disease], these factors are described in the context of the: (1) development of a therapeutic concept for a target disease; (2) pathway to proof of concept via preclinical studies; (3) translation to clinical development; (4) funding and the associated restrictions; (5) assembly of the clinical team; (6) regulatory and compliance requirements; and (7) the iterative process of using lessons learned to inform the next generation therapy. Our experience with each of these factors is demonstrated from our development and clinical translation for two generations of drug product applied to this fatal childhood disorder.Outlined are the descriptions of the hurdles encountered and our solutions, which should be informative for those who seek to develop a gene therapy for a rare disease.",
keywords = "AAV vectors, Batten disease, Central nervous system, Experimental therapies, Gene therapy, Lysosomal storage disorders, Phase I clinical trials in academic setting, Preclinical development, Translational medicine",
author = "Dolan Sondhi and Ronald Crystal and Kaminsky, {Stephen M.}",
year = "2016",
month = "1",
day = "1",
doi = "10.1007/978-1-4899-7654-3_7",
language = "English",
isbn = "9781489976529",
pages = "111--129",
booktitle = "Translational Neuroscience",
publisher = "Springer US",

}

TY - CHAP

T1 - Gene therapy for inborn errors of metabolism

T2 - Batten disease

AU - Sondhi, Dolan

AU - Crystal, Ronald

AU - Kaminsky, Stephen M.

PY - 2016/1/1

Y1 - 2016/1/1

N2 - The development of a gene therapy for inborn errors of metabolism is a multifaceted challenge that rides on organizational, fi nancial, and scientifi c issues.Using our experience with developing a gene therapy strategy for Batten disease [late infantile neuronal ceroid lipofuscinosis (LINCL), CLN2 disease], these factors are described in the context of the: (1) development of a therapeutic concept for a target disease; (2) pathway to proof of concept via preclinical studies; (3) translation to clinical development; (4) funding and the associated restrictions; (5) assembly of the clinical team; (6) regulatory and compliance requirements; and (7) the iterative process of using lessons learned to inform the next generation therapy. Our experience with each of these factors is demonstrated from our development and clinical translation for two generations of drug product applied to this fatal childhood disorder.Outlined are the descriptions of the hurdles encountered and our solutions, which should be informative for those who seek to develop a gene therapy for a rare disease.

AB - The development of a gene therapy for inborn errors of metabolism is a multifaceted challenge that rides on organizational, fi nancial, and scientifi c issues.Using our experience with developing a gene therapy strategy for Batten disease [late infantile neuronal ceroid lipofuscinosis (LINCL), CLN2 disease], these factors are described in the context of the: (1) development of a therapeutic concept for a target disease; (2) pathway to proof of concept via preclinical studies; (3) translation to clinical development; (4) funding and the associated restrictions; (5) assembly of the clinical team; (6) regulatory and compliance requirements; and (7) the iterative process of using lessons learned to inform the next generation therapy. Our experience with each of these factors is demonstrated from our development and clinical translation for two generations of drug product applied to this fatal childhood disorder.Outlined are the descriptions of the hurdles encountered and our solutions, which should be informative for those who seek to develop a gene therapy for a rare disease.

KW - AAV vectors

KW - Batten disease

KW - Central nervous system

KW - Experimental therapies

KW - Gene therapy

KW - Lysosomal storage disorders

KW - Phase I clinical trials in academic setting

KW - Preclinical development

KW - Translational medicine

UR - http://www.scopus.com/inward/record.url?scp=84978288705&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84978288705&partnerID=8YFLogxK

U2 - 10.1007/978-1-4899-7654-3_7

DO - 10.1007/978-1-4899-7654-3_7

M3 - Chapter

SN - 9781489976529

SP - 111

EP - 129

BT - Translational Neuroscience

PB - Springer US

ER -